Table 2. In vitro sensitivity to the Aurora kinases-targeting drugs VX-680 and ZM447439 of a panel of 10 human osteosarcoma cell lines.
|
VX-680 |
ZM447439 |
|||
|---|---|---|---|---|
| Cell linea | Mean IC50 value (μM)b | s.d. | Mean IC50 value (μM) | s.d. |
|
U-2OS |
0.4 |
0.2 |
2.7 |
0.1 |
|
Saos-2 |
0.4 |
0.2 |
2.7 |
0.3 |
|
IOR/OS18 |
2.2 |
0.5 |
5.5 |
1.2 |
|
IOR/OS9 |
0.2 |
0.2 |
0.7 |
0.2 |
|
U-2OS/DX580 |
52.8 |
6.5 |
11.2 |
2.3 |
|
Saos-2/DX580 |
16.3 |
2.5 |
13.8 |
2.3 |
|
U-2OS/MTX300 |
0.6 |
0.1 |
4.3 |
0.4 |
|
Saos-2/MTX300 |
0.3 |
0.2 |
0.6 |
0.2 |
|
U-2OS/CDDP4 μg |
15.2 |
1.2 |
4.4 |
1.0 |
| Saos-2/CDDP6 μg | 8.4 | 2.6 | 2.7 | 0.8 |
a
The cell line panel included four drug-sensitive human osteosarcoma cell lines (U-2OS, Saos-2, IOR/OS18, IOR/OS9) and U-2OS or Saos-2 variants resistant to doxorubicin (U-2OS/DX580, Saos-2/DX580), methotrexate (U-2OS/MTX300, Saos-2/MTX300), or cisplatin (U-2OS/CDDP4 μg, Saos-2/CDDP6 μg).
b
IC50 values were calculated after 96 h of drug treatment. Data refer to the mean IC50±s.d. of three different experiments.